Trial Profile
Multiple Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs SPH 3127 (Primary)
- Indications Hypertension; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 27 Feb 2021 Results of single and multiple ascending dose studies (NCT03128138 and NCT0325599), published in the Clinical Therapeutics
- 27 Feb 2021 Status changed from recruiting to completed, as per results published in the Clinical Therapeutics.
- 27 Oct 2017 Status changed from not yet recruiting to recruiting.